Casaroli-Marano Ricardo P, Nieto-Nicolau Núria, Martínez-Conesa Eva M, Edel Michael, B Álvarez-Palomo Ana
Department of Surgery, School of Medicine and Hospital Clínic de Barcelona (IDIBAPS), University of Barcelona, Calle Sabino de Arana 1 (2nd floor), E-08028 Barcelona, Spain.
CellTec-UB and the Clinic Foundation for Biomedical Research (FCRB), University of Barcelona, Avda. Diagonal 643, E-08028 Barcelona, Spain.
J Clin Med. 2015 Feb 12;4(2):318-42. doi: 10.3390/jcm4020318.
The integrity and normal function of the corneal epithelium are crucial for maintaining the cornea's transparency and vision. The existence of a cell population with progenitor characteristics in the limbus maintains a dynamic of constant epithelial repair and renewal. Currently, cell-based therapies for bio replacement-cultured limbal epithelial transplantation (CLET) and cultured oral mucosal epithelial transplantation (COMET)-present very encouraging clinical results for treating limbal stem cell deficiency (LSCD) and restoring vision. Another emerging therapeutic approach consists of obtaining and implementing human progenitor cells of different origins in association with tissue engineering methods. The development of cell-based therapies using stem cells, such as human adult mesenchymal or induced pluripotent stem cells (IPSCs), represent a significant breakthrough in the treatment of certain eye diseases, offering a more rational, less invasive, and better physiological treatment option in regenerative medicine for the ocular surface. This review will focus on the main concepts of cell-based therapies for the ocular surface and the future use of IPSCs to treat LSCD.
角膜上皮的完整性和正常功能对于维持角膜的透明度和视力至关重要。角膜缘中具有祖细胞特征的细胞群的存在维持着上皮持续修复和更新的动态过程。目前,基于细胞的生物替代疗法——培养的角膜缘上皮移植(CLET)和培养的口腔黏膜上皮移植(COMET)——在治疗角膜缘干细胞缺乏症(LSCD)和恢复视力方面呈现出非常令人鼓舞的临床效果。另一种新兴的治疗方法是结合组织工程方法获取并应用不同来源的人类祖细胞。使用干细胞(如人类成体间充质干细胞或诱导多能干细胞 (iPSC))进行基于细胞的治疗方法的发展,代表了某些眼部疾病治疗方面的重大突破,为眼表再生医学提供了一种更合理、侵入性更小且生理状态更好的治疗选择。本综述将聚焦于眼表基于细胞的治疗方法的主要概念以及iPSC治疗LSCD的未来应用。